Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints

Loading news article.

Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints | WAPE

Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints

Article summary

Related companies

Analyzed by WAPE AI.

Comments —